Key Points
- CEO Martine Rothblatt sold 9,500 United Therapeutics shares at an average price of $504.12, generating $4.79 million and reducing her stake by 2.84% to 324,443 shares.
- United Therapeutics reported quarterly EPS of $7.27, beating estimates of $6.86, while revenue of $783.3 million fell short of expectations and declined 1.9% year over year.
- Analysts maintain a “Moderate Buy” consensus with an average price target of $646, compared with the stock’s opening price of $500.35; institutional investors own 94.08% of shares.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) Director Nilda Mesa sold 228 shares of the business's stock in a transaction on Monday, September 14th. The shares were sold at an average price of $505.87, for a total transaction of $115,338.36. Following the transaction, the director directly owned 5,580 shares of the company's stock, valued at approximately $2,822,754.60. This trade represents a 3.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
United Therapeutics Price Performance
United Therapeutics stock opened at $500.35 on Wednesday. United Therapeutics Corporation has a 12-month low of $397.00 and a 12-month high of $609.35. The stock has a market capitalization of $21.46 billion, a PE ratio of 17.90, a price-to-earnings-growth ratio of 2.52 and a beta of 0.56. The firm has a 50 day simple moving average of $518.75 and a 200-day simple moving average of $540.72.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts' consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company's quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.41 EPS. On average, analysts forecast that United Therapeutics Corporation will post 26.21 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the business. Talon Private Wealth LLC raised its stake in United Therapeutics by 31.8% in the 2nd quarter. Talon Private Wealth LLC now owns 6,753 shares of the biotechnology company's stock worth $3,659,000 after purchasing an additional 1,630 shares in the last quarter. Sequoia Financial Advisors LLC grew its position in shares of United Therapeutics by 4.4% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 2,530 shares of the biotechnology company's stock worth $1,371,000 after purchasing an additional 106 shares in the last quarter. Tidal Investments LLC increased its holdings in shares of United Therapeutics by 1.6% during the second quarter. Tidal Investments LLC now owns 34,012 shares of the biotechnology company's stock worth $18,429,000 after purchasing an additional 547 shares during the period. Archford Capital Strategies LLC bought a new position in shares of United Therapeutics during the second quarter worth approximately $552,000. Finally, Engineers Gate Manager LP acquired a new stake in shares of United Therapeutics in the second quarter valued at approximately $2,524,000. 94.08% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on UTHR. JPMorgan Chase & Co. boosted their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a report on Thursday, July 23rd. Bank of America lowered their target price on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a research note on Friday, July 10th. Royal Bank Of Canada cut their price target on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating for the company in a research note on Thursday, August 6th. Morgan Stanley set a $515.00 price target on United Therapeutics in a research note on Thursday, August 6th. Finally, TD Cowen reaffirmed a "buy" rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $646.00.
Get Our Latest Stock Report on United Therapeutics
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company's products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.
United Therapeutics' PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
